<SUBMISSION>
<ACCESSION-NUMBER>0001144204-05-013729
<TYPE>6-K
<PUBLIC-DOCUMENT-COUNT>3
<PERIOD>20050430
<FILING-DATE>20050503
<DATE-OF-FILING-DATE-CHANGE>20050503
<FILER>
<COMPANY-DATA>
<CONFORMED-NAME>pSivida LTD
<CIK>0001314102
<ASSIGNED-SIC>3826
<IRS-NUMBER>000000000
<STATE-OF-INCORPORATION>C3
<FISCAL-YEAR-END>0630
</COMPANY-DATA>
<FILING-VALUES>
<FORM-TYPE>6-K
<ACT>34
<FILE-NUMBER>000-51122
<FILM-NUMBER>05792750
</FILING-VALUES>
<BUSINESS-ADDRESS>
<STREET1>LEVEL 12 BGC CENTRE
<STREET2>28 THE ESPLANADE
<CITY>PERTH
<STATE>C3
<ZIP>6000
<PHONE>61 8 9226 5099
</BUSINESS-ADDRESS>
<MAIL-ADDRESS>
<STREET1>LEVEL 12 BGC CENTRE
<STREET2>28 THE ESPLANADE
<CITY>PERTH
<STATE>C3
<ZIP>6000
</MAIL-ADDRESS>
</FILER>
<DOCUMENT>
<TYPE>6-K
<SEQUENCE>1
<FILENAME>v017411_6k.htm
<TEXT>
<HTML><HEAD>
<TITLE>
</TITLE>
</HEAD><BODY id=38 bgColor=#ffffff>
<DIV>
<DIV
style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt"
align=center><FONT
style="DISPLAY: inline; FONT-SIZE: 12pt; FONT-FAMILY: Times New Roman"><STRONG>SECURITIES
AND EXCHANGE COMMISSION</STRONG></FONT></DIV>
<DIV
style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt"
align=center><FONT
style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><STRONG>Washington,
D.C. 20549</STRONG></FONT></DIV>
<DIV
style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt"
align=justify>&nbsp;</DIV>
<DIV
style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt"
align=center><FONT
style="DISPLAY: inline; FONT-SIZE: 18pt; FONT-FAMILY: Times New Roman"><STRONG>FORM
6-K</STRONG></FONT></DIV>
<DIV
style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt"
align=justify>&nbsp;</DIV>
<DIV
style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt"
align=center><FONT
style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">REPORT OF
FOREIGN ISSUER<BR></FONT><FONT
style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Pursuant
to Rule 13a-16 or 15d-16 of<BR></FONT><FONT
style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">the
Securities Exchange Act of 1934</FONT></DIV>
<DIV
style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt"
align=justify>&nbsp;</DIV>
<DIV
style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt"
align=center><FONT
style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><STRONG>For
the month of April 2005</STRONG></FONT></DIV>
<DIV
style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt"
align=justify>&nbsp;</DIV>
<DIV
style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt"
align=center><FONT
style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><STRONG>Commission
File Number 000-5112</STRONG></FONT><FONT
style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">2</FONT></DIV>
<DIV
style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt"
align=justify>&nbsp;</DIV>
<DIV
style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt"
align=center><FONT
style="DISPLAY: inline; FONT-SIZE: 12pt; FONT-FAMILY: Times New Roman"><STRONG>pSivida
Limited<BR></STRONG></FONT><FONT
style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">(Translation
of registrant&#8217;s name into English) </FONT></DIV>
<DIV
style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt"
align=justify>&nbsp;</DIV>
<DIV
style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt"
align=justify>&nbsp;</DIV>
<DIV
style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt"
align=center><FONT
style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Level 12
BGC Centre<BR></FONT><FONT
style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">28 The
Esplanade<BR></FONT><FONT
style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Perth WA
6000<BR></FONT><FONT
style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">(Address
of principal executive offices)</FONT></DIV>
<DIV
style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt"
align=justify>&nbsp;</DIV>
<DIV
style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt"
align=justify>&nbsp;</DIV>
<DIV
style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt"
align=left><FONT
style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">(Indicate
by check mark whether the registrant files or will file annual reports under
cover Form&nbsp;20-F or Form&nbsp;40-F). </FONT></DIV>
<DIV
style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt"
align=justify>&nbsp;</DIV>
<DIV
style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt"
align=center><FONT
style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Form 20-F
</FONT><FONT
style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Wingdings">&#253;</FONT><FONT
style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Form
40-F </FONT><FONT
style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Wingdings">o</FONT></DIV>
<DIV
style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt"
align=justify>&nbsp;</DIV>
<DIV
style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt"
align=left><FONT
style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Indicate
by check mark if the registrant is submitting the Form 6-K in paper as permitted
by Regulation S-T Rule 101(b)(1):</FONT></DIV>
<DIV
style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt"
align=justify>&nbsp;</DIV>
<DIV
style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt"
align=left><FONT
style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Indicate
by check mark if the registrant is submitting the Form 6-K in paper as permitted
by Regulation S-T Rule 101(b)(7):</FONT></DIV>
<DIV
style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt"
align=justify>&nbsp;</DIV>
<DIV
style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt"
align=left><FONT
style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Indicate
by check mark whether the registrant by furnishing the information contained in
this Form is also thereby furnishing the information to the Commission pursuant
to Rule&nbsp;12g3-2(b) under the Securities Exchange Act of 1934.</FONT></DIV>
<DIV
style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt"
align=justify>&nbsp;</DIV>
<DIV
style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt"
align=center><FONT
style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Yes
</FONT><FONT
style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Wingdings">o</FONT><FONT
style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;No
</FONT><FONT
style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Wingdings">&#253;</FONT></DIV>
<DIV
style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt"
align=justify>&nbsp;</DIV>
<DIV
style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt"
align=left><FONT
style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">If "Yes"
is marked, indicate below the file number assigned to the registrant in
connection with Rule&nbsp;12g3-2(b): 82- ___. </FONT></DIV>
<DIV
style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt"
align=justify>&nbsp;</DIV>
<DIV
style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt"
align=justify>&nbsp;</DIV>
<DIV id=PGBRK style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt">
<DIV id=FTR>
<DIV id=GLFTR style="WIDTH: 100%" align=left><FONT
style="DISPLAY: inline; FONT-SIZE: 8pt; COLOR: #000000; FONT-FAMILY: Times New Roman"></FONT></DIV></DIV>
<DIV id=PN style="PAGE-BREAK-AFTER: always">
<DIV style="WIDTH: 100%; TEXT-ALIGN: center"><FONT
style="DISPLAY: inline; FONT-SIZE: 8pt" face="Times New Roman"></FONT></DIV>
<DIV style="WIDTH: 100%; TEXT-ALIGN: center">
<HR color=#000000 noShade SIZE=2>
</DIV></DIV>
<DIV id=HDR>
<DIV id=GLHDR style="WIDTH: 100%" align=right><FONT
style="DISPLAY: inline; FONT-SIZE: 8pt; COLOR: #000000; FONT-FAMILY: Times New Roman"></FONT></DIV></DIV></DIV>
<DIV
style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt"
align=justify>&nbsp;</DIV>
<DIV
style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt"
align=center><FONT
style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><STRONG>SIGNATURE
</STRONG></FONT></DIV>
<DIV
style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt"
align=justify>&nbsp;</DIV>
<DIV
style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt"
align=justify>&nbsp;</DIV>
<DIV
style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt"
align=left><FONT
style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Pursuant
to the requirements of the Securities Exchange Act of 1934, the registrant,
pSivida Limited, has duly caused this report to be signed on its behalf by the
undersigned, thereunto duly authorized. </FONT></DIV>
<DIV
style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt"
align=justify>&nbsp;</DIV>
<DIV
style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt"
align=justify>
<TABLE cellSpacing=0 cellPadding=0 width="100%" align=center bgColor=#ffffff
border=0>
  <TR vAlign=top bgColor=#ffffff>
    <TD width="50%"><FONT face="Times New Roman" size=2>&nbsp;</FONT></TD>
    <TD width="1%"><FONT face="Times New Roman" size=2>&nbsp;</FONT></TD>
    <TD width="49%"><FONT face="Times New Roman" size=2>&nbsp;</FONT></TD></TR>
  <TR vAlign=top bgColor=#ffffff>
    <TD><FONT face="Times New Roman" size=2>&nbsp;</FONT></TD>
    <TD colSpan=2><FONT face="Times New Roman" size=2>pSivida
  Limited</FONT></TD></TR>
  <TR vAlign=top bgColor=#ffffff>
    <TD><FONT face="Times New Roman" size=2>&nbsp;<BR>&nbsp;</FONT></TD>
    <TD><FONT face="Times New Roman" size=2>&nbsp;<BR>&nbsp;</FONT></TD>
    <TD><FONT face="Times New Roman" size=2>&nbsp;<BR>&nbsp;</FONT></TD></TR>
  <TR vAlign=top bgColor=#ffffff>
    <TD><FONT face="Times New Roman" size=2>Date:&nbsp; May 3, 2005</FONT></TD>
    <TD><FONT face="Times New Roman" size=2>By:&nbsp;&nbsp;</FONT></TD>
    <TD><FONT face="Times New Roman" size=2>/s/&nbsp;Aaron Finlay</FONT></TD></TR>
  <TR vAlign=top bgColor=#ffffff>
    <TD colSpan=2><FONT face="Times New Roman" size=1>&nbsp;</FONT></TD>
    <TD align=left>
      <HR align=left width="80%" color=#000000 noShade SIZE=2>
    </TD></TR>
  <TR vAlign=top bgColor=#ffffff>
    <TD colSpan=2><FONT face="Times New Roman" size=2>&nbsp;</FONT></TD>
    <TD><FONT face="Times New Roman" size=2><FONT
      style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Aaron
      Finlay<BR></FONT><FONT
      style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><EM>Chief
      Financial Officer and Company
Secretary</EM></FONT></FONT></TD></TR></TABLE></DIV>
<DIV
style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt"
align=justify><FONT size=2></FONT>&nbsp;</DIV>
<DIV
style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt"
align=justify><FONT size=2></FONT>&nbsp;</DIV>
<DIV id=PGBRK style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt">
<DIV id=FTR>
<DIV id=GLFTR style="WIDTH: 100%" align=left><FONT
style="DISPLAY: inline; FONT-SIZE: 8pt; COLOR: #000000; FONT-FAMILY: Times New Roman"></FONT></DIV></DIV>
<DIV id=PN style="PAGE-BREAK-AFTER: always">
<DIV style="WIDTH: 100%; TEXT-ALIGN: center"><FONT
style="DISPLAY: inline; FONT-SIZE: 8pt" face="Times New Roman"></FONT></DIV>
<DIV style="WIDTH: 100%; TEXT-ALIGN: center">
<HR color=#000000 noShade SIZE=2>
</DIV></DIV>
<DIV id=HDR>
<DIV id=GLHDR style="WIDTH: 100%" align=right><FONT
style="DISPLAY: inline; FONT-SIZE: 8pt; COLOR: #000000; FONT-FAMILY: Times New Roman"></FONT></DIV></DIV></DIV>
<DIV
style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt"
align=justify><FONT size=2></FONT>&nbsp;</DIV>
<DIV
style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt"
align=center><FONT
style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><STRONG><EM><U>EXHIBIT
INDEX</U></EM></STRONG></FONT></DIV>
<DIV
style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt"
align=justify>&nbsp;</DIV>
<DIV>
<TABLE cellSpacing=0 cellPadding=0 width="100%">
  <TR>
    <TD vAlign=top align=left width="15%">
      <DIV
      style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt"
      align=left><FONT
      style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><STRONG>EXHIBIT
      99.1:</STRONG></FONT></DIV></TD>
    <TD vAlign=top align=left width="62%">
      <DIV
      style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt"
      align=left><FONT
      style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">pSivida
      ASX Release ESTRO 030505</FONT><FONT
      style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman, serif"><SUP>&nbsp;</SUP></FONT></DIV></TD></TR>
  <TR>
    <TD vAlign=top align=left width="15%">&nbsp;</TD>
    <TD vAlign=top align=left width="62%">&nbsp;</TD></TR></TABLE></DIV>
<DIV
style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt"
align=left><BR></DIV>
<DIV>&nbsp;</DIV>
<DIV>&nbsp;</DIV>
<DIV>&nbsp;</DIV>
<DIV>&nbsp;</DIV>
<DIV>&nbsp;</DIV>
<DIV id=PGBRK style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt">
<DIV id=FTR>
<DIV id=GLFTR style="WIDTH: 100%" align=left><FONT
style="DISPLAY: inline; FONT-SIZE: 8pt; COLOR: #000000; FONT-FAMILY: Times New Roman"></FONT></DIV></DIV>
<DIV id=PN>
<DIV style="WIDTH: 100%; TEXT-ALIGN: center"><FONT
style="DISPLAY: inline; FONT-SIZE: 8pt" face="Times New Roman"></FONT></DIV>
<DIV style="WIDTH: 100%; TEXT-ALIGN: center">
<HR color=#000000 noShade SIZE=2>
</DIV></DIV>
<DIV id=HDR>
<DIV id=GLHDR style="WIDTH: 100%" align=right><FONT
style="DISPLAY: inline; FONT-SIZE: 8pt; COLOR: #000000; FONT-FAMILY: Times New Roman"></FONT></DIV></DIV></DIV></DIV></BODY></HTML>

</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>2
<FILENAME>v017411_ex99-1.htm
<TEXT>
<HTML><HEAD>
<TITLE>
Unassociated Document
</TITLE>
<!-- Licensed to: Vintage Filings-->
<!-- Document Created using EDGARIZER HTML -->
<!-- Copyright 2004 EDGARfilings, Ltd., an IEC company.-->
<!-- All rights reserved EDGARfilings.com -->
</HEAD><BODY id=38 bgColor=#ffffff>
<DIV>
<DIV
style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt"
align=left>&nbsp;</DIV>
<DIV align=left>
<TABLE cellSpacing=0 cellPadding=0 width="100%" border=0>
  <TR>
    <TD vAlign=top align=left width="39%">&nbsp;</TD>
    <TD vAlign=top align=right width="39%"><IMG src="logo.jpg"></TD></TR>
  <TR>
    <TD vAlign=top align=left width="39%">&nbsp;</TD>
    <TD vAlign=top align=right width="39%">&nbsp;</TD></TR>
  <TR>
    <TD style="BORDER-BOTTOM: medium none" vAlign=top align=left width="39%">
      <DIV
      style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt"
      align=left><FONT
      style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><STRONG>ASX/MEDIA
      RELEASE</STRONG></FONT></DIV></TD>
    <TD style="BORDER-BOTTOM: medium none" vAlign=top align=right width="39%">
      <DIV
      style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt"
      align=right><FONT
      style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><STRONG>3</STRONG></FONT><FONT
      style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><SUP><STRONG>rd</STRONG></SUP></FONT><FONT
      style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><STRONG>
      May 2005</STRONG></FONT></DIV></TD></TR></TABLE></DIV>
<DIV
style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt"
align=left><BR></DIV>
<DIV
style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt"
align=center><BR></DIV>
<DIV
style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt"
align=center><FONT
style="DISPLAY: inline; FONT-SIZE: 18pt; FONT-FAMILY: Times New Roman"><STRONG>BrachySil</STRONG></FONT><FONT
style="DISPLAY: inline; FONT-SIZE: 12pt; FONT-FAMILY: Times New Roman"><SUP><STRONG>TM
</STRONG></SUP></FONT><FONT
style="DISPLAY: inline; FONT-SIZE: 18pt; FONT-FAMILY: Times New Roman"><STRONG>to
be Presented at Annual ESTRO Conference</STRONG></FONT></DIV>
<DIV
style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt"
align=center><FONT
style="DISPLAY: inline; FONT-SIZE: 12pt; FONT-FAMILY: Times New Roman"><STRONG>European
Society for Therapeutic &amp; Radiation Oncology</STRONG></FONT></DIV>
<DIV
style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt"
align=justify>
<DIV>
<HR align=left width="100%" color=#000000 noShade SIZE=1>
</DIV><BR></DIV>
<DIV
style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt"
align=justify><FONT
style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Global
nanotechnology company pSivida Limited </FONT><FONT
style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><STRONG>(ASX:PSD,
NASDAQ:PSDV, Xetra:PSI)</STRONG></FONT><FONT
style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"> is
pleased to announce that current data from its lead cancer product
BrachySil</FONT><FONT
style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><SUP>TM</SUP></FONT><FONT
style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"> will be
presented at this year&#8217;s European Society for Therapeutic and Radiation Oncology
Conference in Budapest on 5</FONT><FONT
style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><SUP>th</SUP></FONT><FONT
style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"> May
2005. The conference is an opportunity to share and validate the Company&#8217;s
promising findings with an international scientific, clinical and industrial
audience. </FONT></DIV>
<DIV
style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt"
align=justify><BR></DIV>
<DIV
style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt"
align=justify><FONT
style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Data on
all 8 planned patients has demonstrated marked tumor regression as determined by
CT scanning, up to 100% in some smaller tumors. This study represents the first
step in the regulatory programme leading to product approval and was
specifically focussed on the safety and tolerability of this proprietary
treatment for solid tumors. Importantly the study has found that all patients
tolerated study procedures and the investigational treatment well, with no
significant product-related findings and with all patients discharged from the
clinic the day following treatment.</FONT></DIV>
<DIV
style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt"
align=justify><BR></DIV>
<DIV
style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt"
align=justify><FONT
style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">BrachySil</FONT><FONT
style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><SUP>TM</SUP></FONT><FONT
style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"> is a
micron sized particle in which the isotope 32 phosphorus is immobilised. pSivida
believes that this product is advantageous in that it demonstrates a high degree
of isotope targeting and retention, thus maximising the therapeutic load on the
tumor whilst reducing the risk of radioactivity affecting healthy hepatic tissue
or entering the systemic circulation; a finding borne out by the data from this
critical study.</FONT></DIV>
<DIV
style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt"
align=justify><BR></DIV>
<DIV
style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt"
align=justify><FONT
style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">pSivida&#8217;s
commercialisation strategy as an R&amp;D-focussed business is to seek a sales
and marketing partner for the product.</FONT></DIV>
<DIV
style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt"
align=justify><BR></DIV>
<DIV
style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt"
align=justify><FONT
style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">pSivida
also announced on the 8</FONT><FONT
style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><SUP>th</SUP></FONT><FONT
style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"> April
2005 that the Company would be commencing a&nbsp;Phase IIa human clinical trial
using BrachySil</FONT><FONT
style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><SUP>TM</SUP></FONT><FONT
style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"> later
this year for pancreatic tumors as a second market for BrachySil</FONT><FONT
style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><SUP>TM</SUP></FONT><FONT
style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">, in
addition to liver tumors. It is expected that the BrachySil</FONT><FONT
style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><SUP>TM</SUP></FONT><FONT
style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"> product
will also be applicable to a range of other solid tumor cancer markets which the
Company intends to progressively address.</FONT></DIV>
<DIV
style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt"
align=justify><BR></DIV>
<DIV
style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt"
align=left><BR></DIV>
<DIV
style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt"
align=center><FONT
style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><STRONG>-ENDS-</STRONG></FONT></DIV>
<DIV
style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt"
align=justify><BR></DIV>
<DIV
style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt"
align=justify><FONT
style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><STRONG>Released
by:</STRONG></FONT></DIV>
<DIV
style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 36pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt"
align=justify><BR></DIV>
<DIV align=left>
<TABLE cellSpacing=0 cellPadding=0 width="100%" border=0>
  <TR>
    <TD style="BORDER-BOTTOM: medium none" vAlign=top width="25%">
      <DIV
      style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt"
      align=justify><FONT
      style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><STRONG>In
      Australia:</STRONG></FONT></DIV>
      <DIV
      style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt"
      align=justify><FONT
      style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Josh
      Mann, CFA</FONT></DIV>
      <DIV
      style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt"
      align=justify><FONT
      style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Investor
      Relations</FONT></DIV>
      <DIV
      style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt"
      align=justify><FONT
      style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">pSivida
      Limited</FONT></DIV>
      <DIV
      style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt"
      align=justify><FONT
      style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Tel:
      + 61 8 9226 5099</FONT></DIV>
      <DIV
      style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt"
      align=justify><FONT
      style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">joshuamann@psivida.com</FONT></DIV></TD>
    <TD style="BORDER-BOTTOM: medium none" vAlign=top width="15%">&nbsp;</TD>
    <TD style="BORDER-BOTTOM: medium none" vAlign=top width="25%">
      <DIV
      style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt"
      align=justify><FONT
      style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><STRONG>In
      US:</STRONG></FONT></DIV>
      <DIV
      style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt"
      align=justify><FONT
      style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Beverly
      Jedynak</FONT></DIV>
      <DIV
      style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt"
      align=justify><FONT
      style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">President</FONT></DIV>
      <DIV
      style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt"
      align=justify><FONT
      style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Martin
      E. Janis &amp; Company, Inc.</FONT></DIV>
      <DIV
      style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt"
      align=justify><FONT
      style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Tel:
      312-943-1100 ext. 12</FONT></DIV>
      <DIV
      style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt"
      align=justify><FONT
      style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">bjedynak@janispr.com</FONT></DIV></TD>
    <TD width="35%">&nbsp;</TD></TR></TABLE></DIV>
<DIV
style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt"
align=justify><BR></DIV>
<DIV
style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt"
align=justify><BR></DIV>
<DIV id=PGBRK style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt">
<DIV id=FTR>
<DIV id=GLFTR style="WIDTH: 100%" align=left><FONT
style="DISPLAY: inline; FONT-SIZE: 8pt; COLOR: #000000; FONT-FAMILY: Times New Roman"></FONT></DIV></DIV>
<DIV id=PN style="PAGE-BREAK-AFTER: always">
<DIV style="WIDTH: 100%; TEXT-ALIGN: center"><FONT
style="DISPLAY: inline; FONT-SIZE: 8pt" face="Times New Roman"></FONT></DIV>
<DIV style="WIDTH: 100%; TEXT-ALIGN: center">
<HR color=#000000 noShade SIZE=2>
</DIV></DIV>
<DIV id=HDR>
<DIV id=GLHDR style="WIDTH: 100%" align=right><FONT
style="DISPLAY: inline; FONT-SIZE: 8pt; COLOR: #000000; FONT-FAMILY: Times New Roman"></FONT></DIV></DIV></DIV>
<DIV
style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt"
align=justify><FONT
style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><STRONG>NOTES
TO EDITORS:</STRONG></FONT></DIV>
<DIV
style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt"
align=justify><BR></DIV>
<DIV
style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt"
align=left><FONT
style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><STRONG>pSivida
Limited</STRONG></FONT></DIV>
<DIV
style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt"
align=justify><FONT
style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">pSivida
is a global nanotechnology company committed to the biomedical sector and the
development of products in healthcare. The company&#8217;s focus is the development
and commercialisation of a modified form of silicon (porosified or
nano-structured silicon) known as BioSilicon&#8482;. As a new and exciting
biocompatible material, BioSilicon&#8482; offers multiple potential applications
across the high growth healthcare sector, including controlled release drug
delivery, targeted cancer therapies (including brachytherapy and localized
chemotherapy), tissue engineering and orthopedics. Potential diagnostics
applications are being developed through its subsidiary AION Diagnostics
Limited. </FONT></DIV>
<DIV
style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt"
align=justify><BR></DIV>
<DIV
style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt"
align=justify><FONT
style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">pSivida
owns the intellectual property rights to BioSilicon&#8482; for use in or on humans and
animals. The IP portfolio consists of 24 patent families, 28 granted patents and
over 80 patent applications. The core patent, which recognises BioSilicon&#8482; as a
biomaterial was granted in the UK in 2000 and in the US in 2001. </FONT></DIV>
<DIV
style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt"
align=justify><BR></DIV>
<DIV
style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt"
align=justify><FONT
style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">pSivida
is listed on NASDAQ (</FONT><FONT
style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><STRONG>PSDV</STRONG></FONT><FONT
style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">), the
Australian Stock Exchange (</FONT><FONT
style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><STRONG>PSD</STRONG></FONT><FONT
style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">) and in
Germany on the Frankfurt Stock Exchange on the XETRA system (</FONT><FONT
style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><STRONG>German</STRONG></FONT><FONT
style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">&nbsp;</FONT><FONT
style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><STRONG>Symbol:
PSI. Securities Code (WKN) 358705</STRONG></FONT><FONT
style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">).
pSivida&#8217;s shares also trade in the United Kingdom on the OFEX International
Market Service (IMS) under the ticker symbol </FONT><FONT
style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><STRONG>PSD</STRONG></FONT><FONT
style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">.</FONT></DIV>
<DIV
style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt"
align=justify><BR></DIV>
<DIV
style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt"
align=justify><FONT
style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">The
Company&#8217;s strategic partner and largest shareholder is the QinetiQ group, the
largest science and technology company in Europe. QinetiQ is the former UK
government Defence Evaluation Research Agency and was instrumental in
discovering BioSilicon&#8482;. pSivida enjoys a strong relationship with QinetiQ
having access to its cutting edge research and development facilities. For more
information on QinetiQ visit </FONT><FONT
style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><U>www.qinetiq.com</U></FONT><FONT
style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">.</FONT></DIV>
<DIV
style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt"
align=justify><BR></DIV>
<DIV
style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt"
align=justify><FONT
style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">For more
information visit </FONT><FONT
style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><U>www.psivida.com</U></FONT></DIV>
<DIV
style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt"
align=justify><BR></DIV>
<DIV
style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt"
align=justify><FONT
style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: Arial, sans-serif">This
document contains forward-looking statements that involve risks and
uncertainties. Although we believe that the expectations reflected in such
forward-looking statements are reasonable at this time, we can give no assurance
that such expectations will prove to be correct. Given these uncertainties,
readers are cautioned not to place undue reliance on such forward-looking
statements. Actual results could differ materially from those anticipated in
these forward-looking statements due to many important factors including: our
failure to develop applications for BioSilicon</FONT><FONT
style="DISPLAY: inline; FONT-SIZE: 6pt; FONT-FAMILY: Arial, sans-serif"><SUP>TM</SUP></FONT><FONT
style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: Arial, sans-serif"> due to
regulatory, scientific or other issues. Other reasons are contained in
cautionary statements in the Registration Statement on Form 20-F filed with the
U.S. Securities and Exchange Commission, including, without limitation, under
Item&nbsp;3.D, "Risk Factors" therein. We do not undertake to update any oral or
written forward-looking statements that may be made by or on behalf of
pSivida.</FONT></DIV>
<DIV></DIV></DIV></BODY></HTML>

</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>3
<FILENAME>logo.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 logo.jpg
M_]C_X``02D9)1@`!`@``9`!D``#_[``11'5C:WD``0`$````4```_^X`#D%D
M;V)E`&3``````?_;`(0``@("`@("`@("`@,"`@(#!`,"`@,$!00$!`0$!08%
M!04%!04&!@<'"`<'!@D)"@H)"0P,#`P,#`P,#`P,#`P,#`$#`P,%!`4)!@8)
M#0L)"PT/#@X.#@\/#`P,#`P/#PP,#`P,#`\,#`P,#`P,#`P,#`P,#`P,#`P,
M#`P,#`P,#`P,_\``$0@`2@$&`P$1``(1`0,1`?_$`+L``0`"`@,!`0$`````
M```````'"`8)`P4*!`$"`0$``04!`0``````````````!0(#!`8'"`$0``$#
M!`$#`@(%!PD&!P````$"`P0`$04&!R$2"#$302)183(4"7&!0B.T%76A4K.U
M%C9V-SB1L7)#)'>",V-TA#47$0`!`P($`@8%"@4"!P`````!``(#$00A,1(%
M009187&!$P>1L<$B,O"AT4)28G*R,Q3A(W,T%346@I*BPE,D-O_:``P#`0`"
M$0,1`#\`W^41*(E$2B)1$HB41*(L$Y!Y-T/BO!.['O\`L\+6L4V%>TN4O]:^
MI(O[<=E-W'5]?LH23536EV2Q;N]AM6:Y7!H^60S/<JQ0O(GF;EP.GQ^X4<1K
MA/8QR1R`\O%8]T*Z)=BPFP7WT6^:Z5?40#5WPVM^(^A0S=VNKNO[2'W?MOP'
M<,R.Q1MMW-GE%X_;OQFUS&_I>\Z?R)E1AU1]9CR(TN,XI;2%*;+P25*2'0H`
MA05U3=)L:J;&QX.FM0L*XW/<-OFC_<:',>:>[6HRZAT]:V0UC+<$HB41*(E$
M2B)1$HB41*(E$2B)1$HB41*(E$2B)1$HB41*(E$2B)1$HB41*(OCR.1@8F#+
MR>4F-0,=`:4_-FOK"&VFT"ZE+4;``"@%52]X8"YQH`J19SR;W_E//2M&\5]'
M7L1CNI8R_+^PLO1=>Q][%9;0XE"WU)!Z#U/JE"T]:OB(-%7^A:W)O4UT_P`.
MQ9JZ7NP8/I^6!63\<>(>NXO.M\A<S;#+YPY.=2%+RN?`=QD)RZ5`08*PI*`@
MILDJ]!]E**^.F-*-P"O6>P,8_P`6X<99.EV0[!\NJBN`E*4)2A"0A"``E(%@
M`/0`596P+7XQ&>\I/)G#[7#0)/"'CG)=:Q.6^TQFMG/8ITQR19;<9:$74.ET
M"QLYTR:^&RG$K5`T[I?B0?HPY'[3^KLP]'6M@M8RVM*(E$2B)1$HB41*(E$2
MB)1$HB41*(E$2B)1$HB41*(E$2B)1$HBCC>M,@YP*SCSN37*QT7L;@P93<8.
M)2HJ/S.I*0?F/4D5SKGCDZWW2MZ]TVN-E`R.1L8<`2<W@@'$XD@4"R[:X+/=
MPH>D543ZKNN<U+8HFOYM]Z3@9[B41?O;S<A^.AQ7:VKW65K38*Z*3?TZBU<J
MY6YUW#E_=6;?>N<ZUD(#=;FR/C#C1IUL+A2N#FURQ`''.GMF2L+V_$%.VSX+
M+9M$-.*V63KBHREEY<=L+]X*``"KJ3;MM_+7<^9=DO=S;&+6\?;%M:Z1JUUI
M2N(RI\ZC(9&LKJ;55:V#:=ZP&;R6&<VV;(7CWBU[Z56"Q8$&Q'3H>HKRYS#S
M5S%L^X36;KZ1QC=2H-*\0:<,."FXH(I&!VD8K--`:W?=V,C)<WN=CF8+B&@`
MD.J6I2>X]"4@`"U;KR`SF#FB.65VYR1-C(;@-1)(KTMH/2L:Z\*$@:`:J:L[
MFDZ3J:\A.>5DY,!AME+JQV*E2"`A)5:]NY74_5>NS[YO7^V=E-Q.XROC8UM3
M@99,&@G.FHXNSH*J.BC\:2@PK\R@/!M9WD#(-2]DDY)^+/=[(`@3HT9J.GN(
M<465J4LA('0!-S]-<&V)FX\WW(EW%\Q9(ZC/"ECC:P5.H^&XN>0*8`,JZF94
MI+HMQ1E*CI!*R/=L#LNP8B/PSQ[E).*Q,E*V.0^075]\G'8UXJ6Y$@JL$KFR
M0KM!M9ELE:OF+85Z4V#9X=FLV6L;G.:RM"\U<:DNQ-!Q/1U+5=R?+=N,4?NU
M^-P^J.AOWC\PQZ%,6F:=K?'^L8;3M1Q;6&UW`QQ&QN/:O9*0225*-RI2E$J4
MHFY))-2A))J5DV]NR",1L%&A9/7Q7DHB41*(HUW_`)%AZ6VS%98&0S4I/N,P
MR2E#;=R/<<4/@2"`!U/U5S?G[S$@Y98V-K?$N'BH;6@:W+4X]QH!B>H+,M;0
MS8Y!08YS7NJEE250&D@W]M,<D`'T%RLG^6N'/\Z=_<ZH\(#H#,/G)/SJ2&W1
M=:D/2>91E9K&*V:.S#?E*2W$R3%PTIQ1L$N(43VW]`0;7^BN@\D^<8W"X;:;
MDQK'O(#9&UTEQR#@2=->#@:5S`S6)<[?H&IF/4IZKO"C%5[8\KR@WM.7:QIS
M7[J1D%IB>S&4IKV>_IVJ]LW%OKKS%S'NW-\>\3LMOW'@"4ANEA+=%<*'32E%
M-0LM_#%:5ITJT(]!7IT*%2B)1$HBTN;YN_FC'YXV?'X)SD,:&UO#S&,^ZXAY
M<']U#(=J?;=$4@M>SZ*[OL];UGM;'HX5HN;75WNPO7-;XGAZS3W3337LRHMT
M=8"Z2E$53?,;F[<>!N,\-M^DL8V1E9^Q1L4^C*,N/LAAV-)=44I;=:/=W,IL
M;^E^E7X(P]U"M?YCW27;K<21`$EP&/83U="Q3PJ\B-\\@L/O\_>HV(C/:Q.@
MQL<,3'=CI*)+3JU^X'7GKFZ!:UJ^W$0C(HK'+.\3;DQ[I0!I(I3KKUE7=K'6
MSI1$HB41*(E$769I+:L/E4O);6R8CP=0\VIULI[#<+;192A;U`ZGX5&[RUCK
M&</`+?#?4.!<VFDUU-;[SATM;B1@,57'\0ITJF>Y#%%,!W%IQS)3[B748Z!+
MA#]$I4LR5*[CTZ=OI7CCG,VCA$^V\$$5!$4,T/10N\8G5U:<N*V"WU8UKWD'
MU*0>9O)/6>$M,U]V0RO;>1-FB1D:GH$%??.FOO-BSCB$A2T-=W0J[25'Y4@G
MT]E;"Y]S802..+HV$GK+02M)WG=HMOJ/B>31K1F?X*,-V?DR=GR<J8Q]UF2A
M'>F12"/:><CMJ<;L>ORJ)'6O&/F4`.8[RG_D]@6ZV!)MV$BA("G+@7_ZC8/_
M`'K?]$*[+Y#_`-C=?U&_E6#NGQ-[%S\\/*3K^&8"B$NY`J4F_KV-+M?\EZO>
M>TQ;MENP'`RU]#3]*IVP>^3U+J..&\*<I@&VF<0N>U'*E/(QDUN7W!D]Q,EQ
M7M=W7J;6/PJ*\N6V)N[5C!`9`RM1!.V6N@U/BN=X5>DTH[ZN85R[U:79T[13
MT9JP[;+3(4EEI#06I2UA`";J4;J4;>I)ZDUZ'40!1<E%]6([_LKVFZ+N>WQX
MJ)S^K8/(99F$XHH0\N%'<?2VI0!("BBQ(%5-%2`L>[F,$+Y`*Z6D^@56M3C[
M\3"'E)V9<Y%TB+K6$QF(>F1%XR6Y+F3)H=:;9B,M.H;3=8<4HJ4H!(22:RG6
ME,BM*L^=FO<[QF:0!7`U).&`6!9+\3GD!C.*+'$V'AX$NA;./FRI?W]4<GXO
MA*&PH@>H:(O]-5"T%,UBR<\2M?\`I`-ZR:T[?X+:'PSRWK?-W'V&Y`UA+L>)
MDO<9G8R04E^%,85VO1W>TD$I/4$?:24JZ7M6)(PL-"MYVW<([Z`31Y'AT'H4
M"\N^]_;W+^[>WMQO8O\`S/91Z?5>]>,O-WQ/]R3Z\J,T]FAN7?7O6WV%/!'?
MZU/?&*]8R&H0(<!F*Z^VPE&:B+0@N%[KWJ=2;DA1Z@GI:N]^63]HN]CBAMVL
M+@T"5I`+M?UB\'$@GX2<*>A1=YXC9237J6(3>"V96:FR8^9&.P[SON18;316
MZVE74H"E*``!OV^O2M0O/(Z*?<))8[CP[<NJUC6U<VN.D$D``&NG/"BOMW(A
M@!%2I\8;++#+*G%/*:;2A3R_M+*1;N-OB?6N\P1F.-K"2X@`5.9H,SUE1A-2
MH%SG,L_$[#DL*C!1WFX,Q45+ZGE@J"5=O<0$UPC>_..YV[<YK(6S7".0LU:B
M*T-*THI./;P]@=7,+NN?.1=DXGXLV/D/6->B[1+UA+,J?B)3ZXZ3#+B4/N)6
MVA9NV%=]K>@-=_B:'D`K6MUO)+2W=,QNHMX=2KYXH>84SR*V;:M7S>J0=3G8
M3&LY+&)BS%R#);+OM/W#B$6]LJ;]+_:J[-!X8JH?8.8SN<CF.:&D"HQSZ?8L
MD\M/*.7XW1=)_=6MPMIR>VO3?=A2I2XQ8CQ$M?K![:%D]RW0.OT&OD,/B55_
MF#??\6&4:'%U<*]%/I6;^,',^Q\\\<N\@9_6(6K,OY63!Q$.'(<D^ZS%"$K>
M6IQ"+7=*D@#^;>J9HPPT"RMCW*3<(/&>T-QH*&N7\54';_Q"-IUGE_/\9L\:
M8N5$P^V.:XWEEY!]+BVVYGW7WBV&2`HCYK7J^VV!;6JUVXYODBNG0>&,'%M:
MG@:+:62`"2;`>IK#6]+4KRK^)7/P^X9/"<7:3C,UKV(D.1/[09EU_NG.-+*%
MN,,L%'8V2"$%2E%0^:PO:LUEI45)6@;ASKX<I9`P.:.)X]E%"GDMY<X/R`X4
MPVJ9#69NF\@X?9862GXE=W8;\5$24TMZ.^H(6/G=3\BT`V/12NM7(82QU>"B
M]]Y@9N%FV,M+9`X&G"E#D>_)6`_"X_NUS%_%L3^SOU:O,PI;D3]*7M'M5Q/(
MKR;T?QUPT!_/1W\]LV<"SK^J0EI0\\EH@+>>=5<,M))MW$$D]$I/6UB*(R'!
M;)O&]P[:P%^+CD!\L`M<LO\`%`Y+5*=5"XUU>/"[_P!3'?D37G4I/V0IU*VT
MDV^(0/R5E?LQTK37<\SDX1-IW_2/4KG>,7FEKO/^6<TS+Z^K3=[9B*EQH:7Q
M(AY!MFWO&,X4H6E2`>XH4#\MR%&QM8F@,>/!;+L?,L>XN\,MTOI7I![/H5W:
MQULR41*(OX<0'$+;)("TE)*38BXMT(]#5+V![2T\13#`H%5C>=:R8;<A+;R"
MW8CBG8KV4SL>0AUD=R>]J.YV+NKX?'X5Y:YXY;O-+H2)BYCBYIFO(Y`YF(U,
MB=H?5W#C]6A4W;3-SP[FGUKBXSUCB>;NZ>4<O'CIY58P\7`)EY!Q(;:C0@IM
M#L-*P$I<<00E:@2JPL+`GNZ?Y<^8%C=[9#9W$S8YXFAA:XANH-P:6DT!PI4#
M&HRR4+=[+&V[==!M7$9]'RZ5A?(BT.[OL;C:TN-KE`I6D@@CVT^A%>=O,5[7
M\P7;FD$%^8Q&06R6@I$WL4N\(9"!C\+L+D^:Q";$QM7>^XEL6#0Z_,177?)+
M<+:TV^Z=/(Q@\08N<&_5ZRH_<F%SVT%<%C7)>P(WK.P,-K[S4J!BD+4J6MUM
MEI;J[=Y#CJDILD``&_4WM6M^96_MYKW&*SV]S7QP@DN+FL8YQIJ(<\M;0```
MUQ-:5P5ZSB\!A<_`E2IQ]B9:'E9!X95J(RP&80E9AO(QW;FRBA#([1V=MKD_
M'I75.0-IG8\W$GCA@;I9KNFW$;N!TMC&D::4SXT`Z,&ZD!P%.YM"I7KJBPDH
MBBSG+_);ES_!N=_8'JKC^(=JP-T_M)OP.]16BGP8P>&V#R4T6!G<7%S$%N+E
M)284QI+S7O,075M.%"P4DH4`I-QT/7UJ1N20S!<KY5B9)N#`X`C'/L*O3^)Y
MKN*<X_XYVK[HVC-0-@<Q;<Q*4A:HLJ*Z\MI2K7*0MA)`O8=?IK'LR=1"VKGF
M%IMXWT]X.IW$$^Q?1^&!,?<XUY*@+63'B;0T\RCX!3\)H+/Y_;%?+SX@JN1G
M']M(/O>S^"OIOG'L#=&&W@[]QS$1!1%G`=R5(O?VW$_%-_0CJ/Y*YESWY?6W
M,\8?J\.X8*-?F",]+QQ%<N+3W@]"M;MT)Z0JMY;7-LT>:A^2S(QKC:K1LM%6
MKVE?\+J/I^@V/U5Y<W;ES>^5;@22-?&0?=D83I/8]O3]DT/2%-1S1SB@QZE+
M^B<Q/2),?$;9V7D*#<;,H`0`H]`'DCH`3^D/SCXUU_D7SA?/,RTW6E7$!LHP
MQX"0##'[0H!Q%,1@76W@#4ST*Q->AE$JC.Y?W[V#^+.?TE>'><O_`*2Z_KN_
M,MEM_P!%O8KA[=K<'<=3V34\FVEW'[+BY6,F(5Z>W*94TH_F[KU[C8:4*U2Y
MA;/&Z-V3@1Z5Y]O$G,S>+?*G2L9E6_:D*S$S3\TT5]H2[*#D/J?0]L@(/UVJ
M3G&J.JY%R]*;3<VM=TEI[\/6I#_$5VY>R^02=<80EQO1\'"QK:6U=Q7(F7FN
M7MZ&SR$V^JJ;5M&567SG<&6^$8^J`.\X^U;C.!-!7Q?PYQYHS[3;,_!X9A.8
M2T`$F<\/?EF_Q_7.*Z_&L"1VIQ*Z1M5I^UM8XCF!CVYGYUH%Y5_U6[O_`-T)
M'];5)L_3'8N27_\`JC_ZA_,O0[RC*>@\9\BS8RRU(AZQEWV'$FQ2MN$ZI)!^
MHBHMGQ!=AOG%MO(1F&N]17G\\*==QVS^2G&$#*QFYL*([,R2HSR0M"G8,%]]
MDE*K@]KB4J%_HJ3N#2,KD?+,+9=QC#A4`D^@$CYUL4_$QP&#5Q+J>RG$Q/[0
MQ]JC0&<T&DB4(KL28M;'N@=Q05(2KM)M<7K%LS[Q'4MQYXB9^U8^@U:P*\:4
M."Q/\+C^[7,7\6Q/[._7V\S"Q^1/TI>T>U3]SSX5:WSYOJM[S^_YS#OIQT;&
MQ,5#9C+889CE:OD+J2KYEN*4?K-6H[@L%`%,;MRU%N,WBO>X84H*+HLQLWAM
MP%QD.'-ES6`S;,3'_N_.8N+$:R65FR%H5[DB4F*A90\I1*@I:D]AMVD637T"
M1[M05J2?:MNM_P!N\M(`H12I/6:<>W):H/$R4["\E^('(+JV4N;"(X5<A19?
M:=;4E7T]R%$&LZ?X"N?<NNIN,1'VO6O2G42NUI1$HBJKY->10X>QF,U+38)V
M?F;?2(>AZJRCWE)<>7[29<A`(^1*NB$_IJ%OLA:DWHHM6)R"@MZW?]FT1QC5
M,_!H]I^6/I7-P7P/F]8X_?A\Q[-,Y`W?9YSN:SSTN2M]C'2I'5;$!?RJ0/3W
M"FR5*]!V@5`\Q<N[=OL8CNX6O`R.3F_A</>'I[5E[%!<6,1\20N>XU.-0#T!
M9K,X)UMY15#R<^&D_P#+46W4C\G<D'_::Y5>>1FTR.K#-*P='NN'J!^<K9&[
MG(,P"JZ[/AV]?S^4PK3RI+>/>]I#ZP$J4.T*N0.GQKSKS1L[=GW.:S8XN$;J
M5.!.`/M4M!)XC`[I6<<=\<PMVAY&7*R3T$P'T,I;:0A7<%)[KW5Z5O7EWY=V
M_,\$LLLSF:'!M&@&M17BL:[NS"0`*U4S8OA?3H"T.RTRLNM!OV27`&R1]*&P
MF_Y"379-J\FMBLW!T@?,1]MWN_\`*T-]!)4<_<9794"E6/'8B,-1HS*(\=A(
M0RPVD)0A*>@"4CH`*ZG;V\=O&V.)H:QHH`!0`#(`#)81))J5S5>7Q*(HLYR_
MR6Y<_P`&YW]@>JN/XAVK`W3^TF_`[U%:/O`'_4_I'\-S/]7NU(W7P+E_*/\`
MJ+>QWJ*O7^)R^RGB+0HRG$A][;T+::)^926X,H*('Q`[A?\`+6-9_$>Q;3SR
M1^T9^/V%=/\`A>I4./\`E)9'RJV.*$GZQ#3?_?2\^(*CD4?^O)^(>I7/VOF4
MX')9##1-?<<FP'2TMZ4Z$()'4*2E`42%`@CJ*X+S5YQ_XB[ELXK4F2-VDE[J
M#J(#0201B,1@5TN#;_$:'%V!4LP96,V?"1Y00U.QN5CA2V5@+0H*'S(4DWZ@
M]"#\:ZO8W5IOFWLE`;)#,P$@BH(.;2.HX$<"%@N:Z)],B%2C=,;C\/M.<QF,
M7W0(D@H9%[]ET@J;N?7L42G\U>*N==MMMMWFYMK4UC8^@XTP!+?^$DM[EL5L
M\OC!=FKFZA(ER]6UZ3.O][>@,+>)Z$DH'4_E'6O9?*-Q-<;/:R3_`!NB83U^
MZ,>_-:].`)'`955/-R_OWL'\6<_I*\?\Y?\`TEU_7=^9;!;_`*+>Q7E'H*]P
MC):TO/SYJZBYQ3Y09#8L1&,")L3N/W+$*;5:\DN#[TI-O0F4PM?_`(JE+<ZV
M47(N9[?]GN)D:*!U'#MX_P#4"L2XGB2O(CRWPF1R,<OL;9N#^RYB)(5W=F/B
M.*G*84?B$M-):`'U"OK_`.7'3J6/MP.Y[H'')SRX]@]ZGHP7HTJ+795YJ.5?
M]5N[_P#="1_6U2S/TQV+BE__`*H_^H?S+T+<MI*N*N34I%U*U/-!(^DF"]46
MSXAVKK^X"MM+^!WJ*T->!TIB+Y/\;EY80)+.68:)^*UXR3VC\]JDK@?RRN4\
MJ.`W)E?O?E*V*?B8`_\`X3K)MT&ZP>O_`,&=6+:?'W+<>=_[)OXQZG*//PN/
M[M<Q?Q;$_L[]57F86'R)^E+VCVJ-/.ORCW.7O69X3T/,R,%K6`0W"VR3!46I
M62G/MA;D8O"RTLMI6$%*2.]7=W73857;0BFHK#YJWZ;QC:PFC1@ZF9/1V</2
MIMX%_#TT37]?QFR<SQW-JVZ2P)4C5/>4UBX"E#N#+@:*5R%IN`LE?9>X"2/F
M-N2Y)-&Y*4VGE"&)@?<^\_.GU1]/J6MOQ=2E/DSQ&E`"4)VIL(2/0`!P`"LN
M;X"M)V`4W&+\2]*]1*[6E$41\X<PZYP;QUF]^V(^^(20QAL2E02[/GN@AB.B
M_I<BZC^B@*5\*KC87F@6!N>X1V,!E?PR'2>`^7!5I\3^&MDR.4R7DUS4#D>4
M^0DF1KN.DH)&#Q;PNTAE#ERTM;9"4I'V&K)]5+J[,\?`W(*%V';I'.-[<XRO
MR!^JWV>P=ZOE6.MI2B*B7+.2Q^'VO;<GEIT?&8V'([Y4^4XEIIM(;3U4M1`K
MQ3S[9S7?,]U#`QSY'24#6@N<<!D`M@AFCAMP^1P:T#$DT"S;@:=N&R8S(O8;
M&N:OJ$V2V\WLV4:4WD)[10++Q\%P!3;2@#VOR`.[U0TH?-7H7RJY5NN7[*6.
M\+1+(X.,8(<Z,4P$E,`XYT%>U:[<WYOG!T((C'UB*%WX!T?>=W!6QCL)C,-1
MT+<<2RD)#CJRXM5OBI2B22?B3745]`H*+FHOJ41*(HLYR_R6Y<_P;G?V!ZJX
M_B':L#=/[2;\#O45YX_''4=ZW?E?`8/C3:_[%[P(LZ;@,^5N-I0[%C+=4VM3
M840EU`*#\JAUZI(J4F<`W$8+CVR6TT]T&POTOQ(/8#ZU.?->G^;?,&R8?#\E
M<?;#G9>N)5%Q#>-Q[:,4%.%(<D"1'_Z8J=[1W+4L=!;Y0+5:C=$P5!4ONEKO
M%](UDS'&F5![O;488K:[XC\&SN!>)(NMYUYI_:L[-=S>SAA7>TQ(?0VVB,A?
MZ0:::2E1'0J[B.EJPYI-;JK?>7]K.WVHC=\1-3VGAW+.^3.,U[0L9O"J0WFF
MFPV_&60E$E"?L_-\%CT!/0CITM7%_,KRU._'][9D"Y`H6G!L@&6/!XR!.!%`
M:4JMLL[SPO==EZE!T;"<G8,.P8$#.P&W3^L:B>[[:C]-VB4_G!KB%ML?-^U`
MP01W,8.89JTGO9[O>I(RV[\26GM60ZIQ#L&7FMR=B97B,8A87(2Z09#XO<I2
MD$E-_B5?[#6P<J>4.Y[A<"7<6F&$&K@X_P`Q_$@#ZM>)=0BN`*LSW[&"C,3\
MRMBVVAIM#3:0AMM(2V@>@2!8`?DKU='&V-H:T4`%`.@!09-54C:=%V^;N&:G
MQ<!)?AR,DMUB0GL[5(*[A0NKTM7DSFGD7>[K?;BXBM7NC=,7!PI0MU9YJ>@N
M8VQ`%V-%;D>@KUJ%`K7)^()P+N7*N-X\V;CS5WMFV'7Y,O&Y:'#*!(,*4A+K
M:[.*0"EMQHCUN.^LNVE#*@K3>;MIEO&QOA;J<"0:=!^CVK!?`+QRWSCS=-UW
MCDS2Y.L3(N,8Q>JB?[9<693BERW&PVM=K):0DD_SB!\:JN90X``K%Y1V6:UE
M?).S2:4%>O/Y=:VK5AK?%H:Y%\:>>LKY&;;MF.XOS$O7)W(+^4B9=OV/:<AJ
MR7NAX7=![2CYO2]2+9F!@%>"Y5>;'>OW!\HC.DO)KU56]J?!BY.#-QLYD2(6
M08<C3&%>BVG4E"TGZBDD5'#!=3<T.!!R*\^NZ^+'D1P=R:F;Q_J^>V!C!9`3
M=)W;78JY=VPJ[)<0V'"VXD'L<0XGM/6W<@U)MF8]M"N1W6P7]A<ZH6N=0U:Y
MHKZ?;7U*:.3N%_,SG'CU[>>4$SIF3QLJ(UI_$L%IAAPAP]DB>_&0M+;12V3;
MO4IPW(LA/0VV21L-!Z5*7^U[KN$'B3UJ#[K!3O)'R/8%9G\/;BGD7BW`\GQ>
M0M1G:F_F,CC7L6U-]N[Z&F7DN*3[:U_9*@#>K5R\.(HIKE#;Y[..03-+22*5
M[U5GS,\4N55\O;)R%H>IY'==8W9Q&2>.);,F5"F>VAM]IUA'ZSM*D=Z%)218
MV/45>MYFAM"H'F;8+EUTZ>)I>UV.&)!Z*+O]/U;SVYOP.)XQVG)9?C_C]AG[
MMF]HS49,";(B)';[3Q'9+E$I/:!\J5?\Q?QJEQB8:C$J_;0;U?1B"0ED?%Q%
M#3\Q]O$J+^`/&?GK2>>.,]BSW%N9AZ_@=D8<R664&/;:CA2FR^JSQ/:`>XV'
MI5<LS'-(!4?L^Q7MO>QO?&=(<*E;ZZCEU=*(M?O.6FY'FGRKX2T+/PWSQ3K6
M"E;DXZ%),7*2X[P2IFY!2KM(82I/K[:U6L%7K(C=H82,UJFYV[KW<88GC^4U
MI?U./1ZNXK8"````+`=`!\*QUM:^'*97&82!*RN9R,7$8N$CW)F2FO(88:1>
MW<XZX4I2+GU)KZ!54/D:QI<X@`<2J=;#Y?1MHR\G2_&S4)',VVQR!/S_`,T/
M6L8@^KTN>X$A21]";!7Z*R>E7#&(VETA#6C'%0$F_"9_A6;#*_IR8.T\?;TJ
M+QHS1SJ=VY/R;7+W)_O"4S_TJFM5P,@6(_=D`BTEQLBP>?OZ7`KS[S7YD6.T
MRS#88`;B4_S)]).-*>Z3BZG#*,9T<IVQY?DG+9=P?K+?A;DQO8WIZSCV*?N.
M.0HVO)SAV1O(RI65DIDF<AHO%2@GM4%W((^JU:WY<^8$6T"Y_P`D)7/F>'ZP
MW54TH=52#V>Q3]W:F2FBE`%9K'S6<E!AY".%B/.90^R'$]JNUQ(4.Y/P-CZ5
MZ6L+V.]MX[B.NF1H<*BAHX5%1P*AW-+20>"^RLM4I1$HBB_F]"W.&.6FVT*<
M<7IV<2AM`*E*)@/```=235<?Q#M6#N@K:2_@=ZBM)/@1B\I%\F])>E8N9&93
MCLR%//1W6T"^/=`NI20!>I"Y(T+F7*<3V[@TD')WJ*]`U1BZVE$2B)1$HB41
M*(E$2B)1$HB41*(E$2B)1$HB41*(E$7RSFWWH4QJ*M+<EUAQ$=Q0NE+BDD))
M`^`-`J7`D&BU5:3YT[+Q;CXO'7./$&>E;EHS9Q3N=QR4=\G[N/9;<6T^$`%:
M4B[C;BDK^T!UM68ZW#L6G`K1;;FB2T:(;J%VMF%1QIV^NN.:SUORI\E^761&
MX(\=)6%9<6&W=NVUPIC-]W7N0E?W1LV'6X6Y_P`-4^"QOQ.69_G+^[%+6W(^
M\[+_`+1\Y[%V&'\/>2^4LC'S_E;R_.W..VL/-<<X%U<7%(6%$I#BT)918#H0
MVRE7_J5\,S6X,"JCY?N+IP??REWW&X-]GS"O6KT:=H^H<?8*-K6E:[!UK!Q1
M^JQ\%H-I*K6*W#]IQ9MU4LE1^)K'<2[-;/;VT5NP,B:&CJ64V'T"J:!7TL/H
M%*!%^U]1*(E$2B)1$HB41*(E$2B)1$HB41*(E$2B)1$HB41*(E$2B)1$HB41
M*(E$7`[]H?\`E>GZ?K1%ST1*(E$2B)1$HB41*(E$2B)1$HB41*(E$2B)1$HB
841*(E$2B)1$HB41*(E$2B)1$HB41?__9
`
end
</TEXT>
</DOCUMENT>
</SUBMISSION>
